

THE SECOND EUROPEAN
INFLUENZA
CONFERENCE

MALTA | 11-14 SEPTEMBER 2005



Pocket Guide



ESWI



LUNCHES/DINERS

- All lunches, except Welcome Buffet and Gala Diner, are served in the conference hotel. Please follow the signage to the 7th and 10th floor.
- Welcome Buffet is served at the Radisson SAS hotel on Sunday 11 September at 20h30. Shuttle services are available at all partnering conference hotels. Participants meet in the hotel lobby.
- Gala Dinner is served at La Valletta Hall on Tuesday 13 September at 20h30. Shuttle services are available at all partnering conference hotels. Participants meet in the hotel lobby.

TRANSPORTATION BETWEEN PARTNERING CONFERENCE HOTELS

Shuttles will bring you to and from the Radisson SAS hotel, the Corinthia Marina hotel and the Corinthia San George hotel to the Intercontinental hotel. Please consult the notice board at your hotel lobby for the exact timetable.

DRESS CODE

- Dress code for the conference, the lunches and the Welcome Buffet is casual.
- Dress code for the Gala Dinner is formal.

ESWI BAR

For an enjoyable, informal talk, please visit the ESWI bar on the 7th floor. If you are an Intercontinental Hotel guest, all costs will be charged to your room bill. If you do not stay at the conference hotel, you will be asked to settle your bill immediately (American Express, Visa, Diners and Master credit cards are accepted as of 5 LM).

Pocket Guide

E-MAIL AND INTERNET SERVICE

Free e-mail and internet service is available at the Executive Lounge on the 15th floor, as well as in the Venus room (8th floor). The latter room is freely accessible until 20h, except during database tutorial sessions.

PRIVATE MEETING ROOM

The boardroom on the 15th floor is available for you as an additional meeting location. Please make your free reservation through Mrs Annick Mannaerts at 5225, or (+356) 2376 5225 if you are not using an InterContinental Hotel phone.

AUTOMATED TELLER MACHINES

ATM's are to be found across the road from the hotel, to the right of the Bowling Alley and to the left of the cinemas 7-16. (Look for HSBC signage.)

BANKS

- | | | |
|--------------------|--------------------|-----------------|
| ▪ HSBC Bank | Saint Georges Road | Tel 21 336467/8 |
| ▪ Bank of Valletta | Dragonara Road | Tel 21 310993/4 |
| ▪ Lombard Bank | Dragonara Road | Tel 21 375591 |

EXCHANGE OFFICE

The cashier is located in the lobby and can cash traveller cheques and exchange foreign currency. A 5% exchange fee will be charged.

SAFE DEPOSIT BOX

A laptop sized safe is located in the wardrobe of most rooms and may be operated with a personal code. Items of high value should be stored in the hotel's safe deposit boxes, which are available at the Reception at no extra charge.

CONFERENCE RELATED INQUIRIES

For all conference related inquiries, kindly contact the business centre on the 2nd floor (telephone contact at **5225**, or **(+356) 2376 5225** if you are not using an InterContinental Hotel phone). You will be connected to one of the following persons, dependent on the nature of your inquiry:

Chairpersons – speakers – poster authors:

- Mrs Cris Luyckx

Registration and accommodation:

- Mrs Annick Mannaerts
- Mr Peter De Moor

Press:

- Mr David De Pooter

Technical equipment:

- Mr Steven Roeland

Programme accompanying persons:

- Mrs Annick Mannaerts

Reservation meeting rooms:

- Mrs Annick Mannaerts

ESWI:

- Mr David De Pooter
- Mrs Chris Vanlangendonck

Pocket Guide

HOTEL RELATED INQUIRIES

For all hotel related inquiries, kindly contact the Insider Concierge through the Instant Service Centre on the 3rd floor (telephone contact at **5330**). Examples:


- Adaptors. Voltage on Malta is 230V/50Hz.
- Housekeeping. Housekeeping will be pleased to provide extra pillows, bed boards, duvets, coat hangers...
- Pharmacy
- Medical Doctor
- Public transport
- Taxi service
- Telephone services



LEVEL 1



LEVEL 8



Pocket Guide

LEVEL 2



- Maurice De Cesare level 1
- Neptune level 1
- Cettina De Cesare level 2
- Pre-function area level 2
- Arena level 4
- Venus level 8



FULL CONFERENCE PROGRAMME THE SECOND EUROPEAN INFLUENZA CONFERENCE

11 September 2005

OPENING

14h-16h Cettina De Cesare

CDC Satellite symposium: Solvay Pharmaceuticals

17h-18h30 PLENARY

P1 Arena

Opening of the conference: Influenza as an important issue on the agenda of different stakeholders

SPEAKERS:

- Dr. A.D.M.E. Osterhaus, Erasmus MC, The Netherlands, ESWI chairman
- Dr. K. Stöhr, WHO, Geneva, Switzerland, ESWI Adviser
- Dr. G.A. van EsSEN, University Medical Center Utrecht, Utrecht, The Netherlands, ESWI member
- Dr. A.M. Palache, The Netherlands, ESWI liaison member for industry Dr. W. Deb, CNAM Hygiene and Safety, Paris, France

18h30-20h Cettina De Cesare

Satellite symposium: Hoffmann-La Roche

20h30 WELCOME BUFFET Radisson SAS

12 September 2005

STATE OF THE ART

8h30-9h30 PLENARY

P2 Arena

CHAIR OF THE DAY:

- Dr. A.D.M.E. Osterhaus, Erasmus MC, The Netherlands, ESWI chairman

KEYNOTE LECTURES:

- Dr. J.S. Oxford, Retroscreen, London, United Kingdom
- Dr. A. Garcia-Sastre, Mount Sinai School of Medicine, New York, USA

9h30-11h SESSIONS

S1 Maurice De Cesare

Epidemic and pandemic influenza, WHO cares and HOW?

CHAIR:

- Dr. A.D.M.E. Osterhaus, Erasmus MC, The Netherlands, ESWI Chairman
- Dr. J.S. Oxford, Retroscreen, London, United Kingdom

SPEAKERS:

- S1-1 Dr. E. Bersabel, Public Health Agency of Canada: From Awareness to Action- Getting Canada prepared on the Path to Pandemic Readiness
- S1-2 Dr J. Van-Tam, Consultant Epidemiologist, Health Protection Agency Centre for Infections, UK:
Influenza pandemic contingency planning: capability and capacity in Europe
- S1-3 Dr. G.A. van EsSEN, University Medical Center Utrecht, Utrecht, The Netherlands, ESWI member: The macroepidemiology of Influenza vaccination (MIV) in 56 countries, 1997-2003- a report from the MIV study group
- S1-4 Dr. F. Karcher (tbc)

S2 Arena

Pathogenesis

CHAIR:

- Dr. Y. Kawaoka, University of Wisconsin-Madison, Madison, USA

SPEAKERS:

- S2-1 Dr. J. Katz, Centers for Disease Control & prevention, Atlanta, United States: Differential Virulence in Ferrets of Influenza A5N1 Viruses Isolated in Asia
- S2-2 Dr. R. Webster, St. Jude Children's Research Hospital, Memphis -Tennessee, United States
- S2-3 Dr. Y. Kawaoka, University of Wisconsin-Madison, Madison, USA
- S2-4 Dr. G. Rimmelzwaan, Erasmus MC, Rotterdam, The Netherlands

S3 Cettina De Cesare

Societal impact and methodological approach

CHAIR:

- Dr. K. Nichol, University of Minnesota, Minneapolis, USA

SPEAKERS:

- S3-1 Dr. A. Monto, University of Michigan, USA
- S3-2 Dr. W. Beyer, National Influenza Center Erasmus MC, Rotterdam, The Netherlands
- S3-3 Dr. D. Fleming, Birmingham Research Unit, Birmingham, United Kingdom
- S3-4 Dr. K. Nichol, University of Minnesota, Minneapolis, USA

11h-11h30	COFFEE	2nd Floor Pre-function area
11h30-13h	SESSIONS	
S4		Maurice De Cesare

Economic and social impact of epidemic and pandemic influenza**CHAIR:**

- Dr. T.D. SZUCS, University of Zurich, Switzerland, ESWI Member Dr. K. Nichol, University of Minnesota, Minneapolis, USA

SPEAKERS:

- S4-1 Dr. M. Meltzer, Centers for Disease Control and Prevention (CDC), Atlanta, United States: The economics of controlling pandemic and non-pandemic influenza
- S4-2 Dr. E. Hak, UMC Utrecht, Utrecht, The Netherlands: Predicting morbidity and mortality associated with pandemic influenza in The Netherlands.
- S4-3 Dr. J. Chancellor: Lowering the age threshold for routine influenza vaccination to 50 years: costeffectiveness analysis for European countries
- S4-4 Mrs. C. Ammon, Business Group Influenza WWL B201, Petit-Lancy/Geneva, Switzerland: A public health approach to improve the vaccination coverage against influenza amongst Healthcare Workers (HCW)
- S4-5 Dr. K. Nichol, University of Minnesota, Minneapolis, USA

S5		Cettina De Cesare
-----------	--	-------------------

Misconceptions**CHAIR:**

- Dr. A. Monto, University of Michigan, USA
- Dr. A.D.M.E. Osterhaus, Erasmus MC, The Netherlands, ESWI Chairman

Multimedia and audience interaction

S6		Arena
-----------	--	-------

Animal influenza and Ecology**CHAIR:**

- Dr. A.M. Fouchier, Erasmus MC, Rotterdam, The Netherlands

12 SEPTEMBER 2005

SPEAKERS:

- S6-1 Dr. Klimov, Influenza Branch CDC, Atlanta, United States
- S6-2 Dr. V. Munster, Erasmus MC, Rotterdam, The Netherlands : Avian Influenza surveillance in Northern Europe: characterization of unusual strains and strains related to HPAI outbreaks
- S6-3 Dr. R. Donis, Centers for Disease Control and Prevention, Atlanta, USA: Interspecies transmission of equine influenza virus to dogs

13h-14h30	LUNCH	7th and 10th Floor
14h-14h30	POSTER TOUR ARENA	
14h30-16h	SESSIONS	
S7		Maurice De Cesare

Influenza surveillance: why?**CHAIR:**

- Dr. J. van der Velden, Radboud University Medical Centre Nijmegen, The Netherlands

SPEAKERS:

- S7-1 Dr. I. BROWN, VLA-Weybridge, Addlestone, United Kingdom: Active surveillance of avian influenza in European Union Member States
- S7-2 Dr. W. Haas, Robert Koch Institute, Berlin, Germany, ESWI adviser: National influenza surveillance in the European context: the example of Germany
- S7-3 Dr. K.Stöhr, WHO, Geneva, ESWI adviser

S8		Arena
-----------	--	-------

Development of diagnostic methods**CHAIR:**

- Dr. R. Donis, Centres for Disease Control and Prevention, Atlanta, USA

SPEAKERS:

- S8-1 Dr. S. Lindstrom, Centers for Disease Control and Prevention, Atlanta, USA: Real-time RT-PCR method for rapid detection and characterization of influenza: testing of suspect H5N1 human cases
- S8-2 Dr. T. Odagiri, National Institute of Infectious Diseases, Tokyo, Japan: Development of H5-LAMP (Loop-Mediated Isothermal Amplification) System for Rapid Diagnosis of H5 Avian Influenza Virus Infection
- S8-3 Dr. D. L. Suarez, Southeast Poultry Research Laboratory, Athens, Georgia, USA: Implementation of real-time RT-PCR for Rapid Diagnosis of AIV
- S8-4 Dr. F.H.M. Pistoör, ViroClinics BV, Rotterdam, The Netherlands: Inhibition of neuraminidase activity by influenza virus-specific antibodies. A novel approach for (sub)typing neuraminidases.

12 SEPTEMBER 2005

11

S9

Cettina De Cesare

Virus structure and replication

CHAIR:

- Dr. A. Garcia-Sastre, Mount Sinai School of Medicine, New York, USA

SPEAKERS:

- S9-1 Dr. M. Amorim, University of Cambridge, Cambridge, United Kingdom:
A second requirement for RNA Pol II in the influenza virus lifecycle
- S9-2 Dr. E. Prokudina, Institute of virology, Moscow, Russia: Formation of unfolded Nucleocapsid Protein (NP) in influenza virus infected cells
- S9-3 Dr. S. van der Werf, Institut Pasteur, Paris, France:
Cloning of the chicken RNA polymerase I promoter and use for reverse genetics of influenza A viruses in avian cells

16h-16h30

COFFEE

2nd Floor Pre-function area

16h30-18h

SESSIONS

S10

Cettina De Cesare

Recommendations and guidelines on influenza vaccination and treatment

CHAIR:

- Dr. G.A. van Essen, Julius Center, University Medical Center, Utrecht, The Netherlands, ESWI Member

SPEAKERS:

- S10-1 Dr. A. Windak, College of Family Physicians in Poland, Kraków, Poland:
Polish Family Doctors against Influenza
- S10-2 Dr. Kossow, University of Bremen, Achim, Germany:
Influenza Plan for Germany
- S10-3 Dr. J. Treanor, University of Rochester, United Kingdom: Recommendations and guidelines on influenza vaccination and treatment - USA perspective
- S10-4 Dr. C. Brotons, European Network for Prevention, Barcelona, Spain:
The role of European general practitioners in influenza vaccination

S11

Arena

Clinical Impact

CHAIR:

- Dr. K.G. Nicholson, Leicester Royal Infirmary, United Kingdom

SPEAKERS:

- S11-1 Dr. A. Ortvist, Karolinska Institute, Stockholm, Sweden:
re-evaluation of the effectiveness of influenza vaccination in prevention of mortality in the elderly
- S11-2 Dr. K. Nichol, University of Minnesota, Minneapolis, USA:
burden of influenza-like illness among university and college students: 2002-03 and 2003-04 cohorts
- S11-3 Dr. H.Rebello-de-Andrade, Instituto Nacional De Saude DR Ricardo Jorge, Lisboa, Portugal: the role of clinical diagnosis; signs and symptoms of influenza infection
- S11-4 Dr. M. Tsolia, University of Athens, P&A Kyriakou Children's Hosp, Athens, Greece:
impact of influenza infection on children examined as outpatients and their families/influenza infection in hospitalized children

18h15-19h45

Cettina De Cesare

CDC Satellite symposium, Baxter Vaccines

20h

Variety of locations

Sponsor evening

13 September 2005

INTERACTION BETWEEN SCIENCE AND POLICY

8h30-9h30

PLENARY

P3

Arena

CHAIR OF THE DAY:

- Dr. D.J. Smith, University of Cambridge, United Kingdom, ESWI Member

KEYNOTE LECTURE

- Dr. D. Salisbury, Department of Health, United Kingdom
- Dr. A.D.M.E. Osterhaus, Erasmus MC, The Netherlands, ESWI chairman

9h30-11h

SESSIONS

S12

Maurice De Cesare

How to develop and implement pandemic preparedness plans

CHAIR:

- Dr. D.S. Fedson, France

SPEAKERS:

- **S12-1** Dr. P. van Dalen, Ministry of Health, The Netherlands: Pandemic flu as a challenge for infectious disease preparedness
- **S12-2** Dr. J. Löwer, Paul-Ehrlich-Institut, Langen, Germany: Design and procurement of pandemic influenza vaccines: critical factors
- **S12-3** Dr. T. Melillo, Disease Surveillance Unit, Msida, Malta

S13

Neptune

Diagnosis and treatment in primary health care**CHAIR:**

- Dr. M. Tashiro, National Institute of Infectious Diseases, Tokyo, Japan

SPEAKERS:

- **S13-1** Dr. D. Fleming, Birmingham Research Unit, Birmingham, United Kingdom: The recognition and differential impact of influenza and respiratory syncytial virus infections
- **S13-2** Dr. L. Jennings, Canterbury Health Laboratories, Christchurch, New Zealand: Diagnosis and Treatment in Primary Health Care
- **S13-3** Dr. C. Hannoun, Institut Pasteur Paris, Montrouge, France, ESWI Member: Is biological diagnosis of influenza possible in practice?
- **S13-4** Dr. P. Glezen

S14

Arena

Vaccines: new approaches and methods for evaluation**CHAIR:**

- Dr. J. Wood, NIBSC Department of Virology, Hertfordshire, United Kingdom

SPEAKERS:

- **S14-1** Dr. J.A. Desheva, Institute of Experimental Medicine, St. Petersburg, Russia: Development and characterization of H5 influenza Live attenuated Vaccine for potential Pandemic
- **S14-2** Dr. E. De Wit, Erasmus MC, Rotterdam, The Netherlands: Protection of mice against lethal infection with highly pathogenic H7N2 influenza A virus using a recombinant low pathogenic vaccine strain
- **S14-3** Dr. T. Odagiri, National Institute of Infectious Diseases, Tokyo, Japan: Inactivated influenza H5N1 whole-virus vaccine with alum-adsjuvant induces protective immunity against lethal challenge with homologous and heterologous highly pathogenic H5N1 avian influenza viruses.

- **S14-4** Dr. X. Saelens, Gent University, Gent, Belgium: Universal Influenza A Vaccine: Optimization of M2-Based Constructs
- **S14-5** Dr. J. McElhane, University of Connecticut Health Center, Farmington, United States, ESWI adviser: T-Cell Responses And Not Serologic responses To Vaccination Correlate With Laboratory-Diagnosed Influenza in the Elderly

S15

Cettina De Cesare

Surveillance & Epidemiology**CHAIR:**

- Dr. J. van der Velden, Netherlands School of Public Health, The Netherlands

SPEAKERS:

- **S15-1** Dr. J. Oepfen, Max Planck Institute for Demographic Research, Rostock, Germany: An epidemiological analogue to sero-archaeology for influenza: new insights into viral evolution since 1781
- **S15-2** Dr. C. Viboud, Fogarty International center NIH, Bethesda, United States: An unusually deadly influenza epidemic: Comparison of mortality impact of the 1951 epidemic in England & Wales, Canada and the United States
- **S15-3** Dr. A. Meijer, European Influenza Surveillance Scheme, Utrecht, The Netherlands: Programme of the Community Network of Reference Laboratories for Human Influenza in Europe to improve influenza surveillance
- **S15-4** Dr. A.C. G. Voordouw, Medicines Evaluation Board / Erasmus MC, The Hague, The Netherlands: Annual revaccination against influenza and mortality risk in community dwelling elderly persons.
- **S15-5** Dr. J. Legrand: Assessing the field efficacy of the influenza vaccine

11h-11h30	COFFEE	2nd Floor Pre-function area
11h30-13h15	PLENARY	
P4		Arena

- **P4-1** Dr. A. Croisier, World Health Organization, Switzerland, ESWI Adviser: The Global Agenda on Influenza: status and the importance of implementation
- **P4-2** Dr. J. Giesecke, Head of Scientific Advice of the ECDC: Pandemic preparedness: Is the EU heading in the right direction?
- **P4-3** Pandemic preparedness: do we need antiviral stocks and when will vaccines be available (round table discussion).

CHAIR:

- Dr. A.D.M.E. Osterhaus, Erasmus MC, The Netherlands, ESWI chairman

SPEAKERS:

- Dr. N. J. COX, Centers for Disease Control and Prevention, Atlanta, USA
- Dr. D.S. Fedson, France
- Dr. L. Hessel, European Vaccine Manufacturers
- Dr. D. Reddy, Roche, Task Force Leader pandemic planning, Switzerland
- Dr. J. Purves, EMEA

13h15-14h30	LUNCH	7th and 10th Floor
14h-14h30	POSTER TOUR ARENA	
14h30-16h	SESSIONS	

S16	Maurice De Cesare
------------	-------------------

Influenza as an issue on the agenda of policy makers and government representatives: what can we do? What do we need?

CHAIR:

- Dr. T.D. SZUCS, University of Zurich, Switzerland, ESWI Member

S17	Maurice De Cesare
------------	-------------------

Influenza as an issue on the agenda of health care workers: what can we do? What do we need?

CHAIR:

- Dr. K. Nichol, University of Minnesota, Minneapolis, USA

S18	Arena
------------	-------

Antivirals**CHAIR:**

- Dr. M. C. Zambon, Health Protection Agency, United Kingdom

SPEAKERS:

- S18-1 Dr. N. Sugaya, Keiyu Hospital, Yokohama, Japan: Lower Clinical Effectiveness of Oseltamivir against Influenza B infection
- S18-2 Dr. B. Nordstrom, Ingenix i3 Epidemiology, Auburndale, United States: Reduction of Influenza Complications Following Oseltamivir use
- S18-3 Dr. M. Medina, Centers for Disease Control and Prevention, Atlanta, United States: Susceptibility of Influenza A(H5N1) and A(H3N2) viruses isolated over the last three years to neuraminidase inhibitors
- S18-4 Dr. A. Hay, Institute of Medical Research, London, United Kingdom: Structural studies on Influenza A virus Neuraminidases
- S18-5 Maria Zambon, Health Protection Agency, United Kingdom

S19	Cettina De Cesare
------------	-------------------

Immunology**CHAIR:**

- Dr. J. Yewdell, National Institute of Allergy and Infectious Diseases, Bethesda, USA

SPEAKERS:

- S19-1 Dr. R.J. COX, University of Bergen, Bergen, Norway: Analysis of the B and T cellular responses induced locally and systematically upon influenza vaccination in man
- S19-2 Dr. G. Rimmelzwaan, Erasmus MC, Rotterdam, The Netherlands: Escape from CTL by influenza A viruses is common and applies for epitopes restricted by multiple HLA molecules
- S19-3 Dr. T. Schumacher, The Netherlands Cancer Institute, The Netherlands: High throughput analysis of virus-specific T cell responses
- S19-4 Dr. J. Yewdell, National Institute of Allergy and Infectious Diseases, Bethesda, USA: Immunodominance in CD8+ T Cell Responses to Influenza A Viruses: Dissecting the Mechanism in the Mouse Model

16h-16h30	COFFEE	2nd Floor Pre-function area
16h30-17h30	PLENARY	

P5	Arena
-----------	-------

How can we join forces to reduce the impact of influenza?

Scientists, health care workers, policy makers and government representatives engage in an open debate.

17h30-19h	Maurice De Cesare
-----------	-------------------

MDC Satellite symposium, European Vaccine Manufacturers

16h30-17h30	GALA DINNER	La Vallette
-------------	-------------	-------------

14 September 2005

NEW DEVELOPMENTS

8h30-9h30	PLENARY	
-----------	---------	--

P6	Arena
-----------	-------

CHAIR OF THE DAY:

- Dr. J.A. Hay, Institute of Medical research, London, United Kingdom
- Young scientists present their work, Award for promising young scientist.

SPEAKERS:

- P6-1 Femke Berkhoff, Erasmus MC, Rotterdam, The Netherlands: Functional constraints of influenza A virus epitopes limit escape from CTL
- P6-2 Catherine Thompson, University of Reading, Reading, United Kingdom: Evolution of H3N2 influenza A viruses in humans and the effect on sialic acid binding
- P6-3 Victor Huber, St. Jude Children's Research Hospital, Memphis, United States: A Prime-Boost Vaccination Regimen Using DNA and Venezuelan Equine Encephalitis Virus Viral Replicon Particles (Vrps) as Vectors for Influenza Hemagglutinin That Stimulates Strong Anti-Influenza Immunity

9h30-11h

SESSIONS

S20

Arena

Genetics and evolution**CHAIR:**

- Dr. N. J. COX, Centers for Disease Control and Prevention, Atlanta, USA

SPEAKERS:

- S20-1 Dr. Y. Pu Lin: Genetic relationships among recent influenza B viruses
- S20-2 Dr. B. Schweiger, Robert Koch Institute, Berlin, Germany: Reassortment between human influenza A/H3N2 viruses - an important strategy for the evolution of H3N2 viruses?
- S20-3 Dr. L. Haaheim: Identification of genetic diversity in vitro by cultivating influenza A(H3N2) virus in the presence of post-infection sera from small children.
- S20-4 Dr. D. Smith, University of Cambridge, Cambridge, United Kingdom, ESWI Member: Punctuated Equilibria and the Evolutionary Dynamics of Influenza A(H3N2) virus
- S20-5 Dr. R. Donis, Centers for Disease Control and Prevention, Atlanta, USA: Molecular properties and epidemiology of the hemagglutinin of H5N1 influenza viruses isolated in 2004 and 2005.

S21

Cettina De Cesare

Late breakers**SPEAKER:**

- S21-1 Dr. A. Linde, Swedish Institute for Infectious Disease Control, Solna, Sweden ESWI's National Influenza Networks: concept and achievements

11h-11h30	COFFEE	2nd Floor Pre-function area
11h30-13h	SESSIONS	
S22		Cettina De Cesare

Socio-economics**CHAIR:**

- Dr. E. Hak, UMC Utrecht, The Netherlands

SPEAKERS:

- S22-1 Dr. E. Hak, UMC Utrecht, The Netherlands: Cost-effectiveness and cost-utility of vaccinating against influenza among children 18 years and younger in the United States.
- S22-2 Dr. J. M. Simmerman, US Centers for Disease Control, Nonthaburi, Thailand: The Cost of Influenza in Thailand
- S22-3 Dr. J. Medema, Solvay Pharmaceuticals bv, Weesp, The Netherlands: Increasing vaccination rates in the European Union
- S22-4 Dr. E. Vergu, INRA, Jouy-en-Josas, France: Simulating global public health control measures for pandemic influenza

S23

Arena

Breaking areas**CHAIR:**

- Dr. R.G. Webster, St. Jude's Children's research hospital, Memphis, USA

SPEAKER:

- S23-1 Dr. C. Bruschke, Organisation Mondiale de la Santé, Paris, France
- S23-2 Dr. A.D.M.E. Osterhaus, Erasmus MC, The Netherlands, ESWI Chairman: A Global taskforce for Influenza

13h-13h15

PLENARY

P7

Arena

CLOSING REMARKS:

- Dr. A.D.M.E. Osterhaus, Erasmus MC, The Netherlands, ESWI Chairman

13h15-14h30

LUNCH

7th and 10th Floor

13h30-14h0

PRESS STATEMENT

Maurice De Cesare



MAIN SPONSORS

Solvay
Pharmaceuticals



SPONSORS

CHIRON | VACCINES

Berna >B-